Zura Bio (NASDAQ:ZURA) Coverage Initiated at Wedbush

Research analysts at Wedbush assumed coverage on shares of Zura Bio (NASDAQ:ZURA) in a research report issued to clients and investors on Monday. The brokerage set an “outperform” rating and a $15.00 price target on the stock. Wedbush’s target price points to a potential upside of 149.58% from the company’s previous close.

Other analysts have also recently issued research reports about the company. Leerink Partners raised Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd. Wall Street Zen downgraded shares of Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Finally, Chardan Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Zura Bio in a report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $11.60.

Zura Bio Price Performance

Shares of ZURA stock opened at $6.01 on Monday. Zura Bio has a one year low of $0.97 and a one year high of $6.63. The company’s fifty day moving average price is $4.95 and its 200-day moving average price is $3.56. The company has a market capitalization of $390.77 million, a price-to-earnings ratio of -9.25 and a beta of 0.21.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Equities research analysts expect that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zura Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Allworth Financial LP purchased a new stake in shares of Zura Bio during the 4th quarter valued at about $30,000. Savant Capital LLC raised its position in Zura Bio by 190.4% during the second quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock valued at $34,000 after purchasing an additional 21,249 shares during the period. Scientech Research LLC bought a new stake in shares of Zura Bio in the 3rd quarter valued at approximately $45,000. AQR Capital Management LLC purchased a new position in shares of Zura Bio in the 1st quarter worth approximately $72,000. Finally, Forefront Wealth Partners LLC purchased a new position in shares of Zura Bio in the 3rd quarter worth approximately $93,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.